Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$41.19 - $52.25 $86,499 - $109,725
-2,100 Reduced 7.75%
25,000 $1.26 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $36,890 - $56,880
1,000 Added 3.83%
27,100 $1.27 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $616,818 - $831,472
-16,550 Reduced 38.8%
26,100 $998,000
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $33,975 - $55,676
1,016 Added 2.44%
42,650 $2.34 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $422,585 - $1.42 Million
41,634 New
41,634 $1.42 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.38B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.